Data From Mount Sinai Biobank Provides Critical Insight Into Personalized Medicine
Mount Sinai researchers find that population labels may not be helpful in predicting disease risk or guiding how a patient will respond to certain medications, as previously thought.
Researchers at Mount Sinai School of Medicine, in collaboration with researchers at Loyola University Chicago Stritch School of Medicine, have made a critical discovery that may lead scientists to abandon the use of broad conventional ethnic labels—African-American, Hispanic, and Caucasian—to estimate a patient’s genetic risk for disease. This first-of-its kind study conducted with diverse patients receiving care at a single urban academic medical center, marks an important step in the clinical application of personalized medicine. The data are published online in the peer-reviewed journal PLoS ONE.
The Mount Sinai Biobank, a program of the Charles R. Bronfman Institute for Personalized Medicine, enrolls consented patients representing the diverse communities surrounding The Mount Sinai Medical Center, who confidentially provide DNA and plasma samples to aid in genomic and personalized medicine research. Researchers used state-of-the-art genomic technology to determine the genetic make-up, or genotype, of nearly 1,000 local Biobank participants who self-identified as European American, African-American, or Hispanic. They found that there was a continuum in ancestral genetic heritage at the individual level of African-American and Hispanic patients receiving care at Mount Sinai—meaning considerable fractions of their genome came from mixed European or African ancestry, respectively—and with it genetic variants that indicate risk for developing disease.
"Our data indicate that historical population labels may not be helpful in predicting disease risk or guiding how a patient will respond to certain medications," said Erwin Bottinger, MD, Director of the Bronfman Institute, and the Irene and Dr. Arthur M. Fishberg Professor of Medicine. "Rather, a spectrum of mixed ancestry is emerging in the largest U.S. minority groups. These findings further validate the importance of considering the unique genotype of the individual patient rather than grouping patients by self-reported ethnicity."
To date, genomic studies have overwhelmingly focused on populations with European ancestry, causing concerns about the applicability of their findings to determine disease risk and responsiveness to therapies for non-European, and in particular, mixed genetic backgrounds receiving care at urban medical centers.
"Our data indicate how important it is to evaluate patient populations at a local level," said Dr. Bottinger. "Now that we can determine the genotypic breakdown of our patients, we can begin to develop tests and tailor therapies for the diverse community we serve, allowing us to provide highly effective, personalized care."
On the basis of their findings, researchers at the Bronfman Institute are evaluating the clinical use potential of hundreds of genetic markers for major diseases, such as heart disease, kidney disease, liver disease, and diabetes, and various drug responses, in all Biobank samples. The goal is to identify those genetic markers that may be useful to predict disease risk in local people with mixed genetic backgrounds. The project will be completed with all 20,000 Biobank samples by the end of 2011.
"We anticipate the results, for the first time, will lead us to select the right genetic markers, and allow us to bring personalized genomic medicine to patients in the diverse Mount Sinai community who are being treated for diabetes and heart, kidney, and liver diseases, among other conditions," says Dr. Bottinger.
Also, Dr. Bottinger and his team at the Charles R. Bronfman Institute for Personalized Medicine are able to help guide other medical centers around the country in replicating their study. Additionally, they are continuing to broaden the number of consented donors in the Mount Sinai Biobank in an effort to uncover more genetic markers of disease and connections between self-identified population groups.
This study was supported by The Andrea and Charles Bronfman Philanthropies, Inc.
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of few medical schools embedded in a hospital in the United States. It has more than 3,400 faculty in 32 departments and 15 institutes, and ranks among the top 20 medical schools both in National Institute of Health funding and by U.S. News & World Report. The school received the 2009 Spencer Foreman Award for Outstanding Community Service from the Association of American Medical Colleges.
The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation's oldest, largest and most-respected voluntary hospitals. U.S. News & World Report consistently ranks The Mount Sinai Hospital among the nation's best hospitals based on reputation, patient safety, and other patient-care factors. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 530,000 outpatient visits took place.